knowledge -WSS

knowledge

author：hotspot 2025-10-06 10:56:55 Page View：35146

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Boston hospital trains restaurant workers on naloxone for overdoses
Next article： The high cost of giving birth even with insurance

comprehensive

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

The United States must get value

AdobeThechanginglandscapeofdrugpricingpolicyintheU.S.hasimplicationsfortheglobalpaceanddirectionofin

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

ReporterNicholasFlorkoholdsthejugof"petmilk"fromMarylandthathepickedupinWashington,D.C.NicholasFlork